Oncology (Williston Park, N.Y.)最新文献_第4页

Julie M. Vose, MD, President of ASCO--and Editor-in-Chief of ONCOLOGY--Discusses Her New Role and the Importance of Investing Wisely in Cancer Research. Julie M. Vose，医学博士，ASCO主席兼肿瘤学主编，讨论了她的新角色和在癌症研究中明智投资的重要性。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Julie M Vose

引用次数: 0

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy: A Review of the Evidence. 新辅助化疗后乳房切除术放疗:证据回顾。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Christina Hunter Chapman, Reshma Jagsi

{"title":"Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy: A Review of the Evidence.","authors":"Christina Hunter Chapman, Reshma Jagsi","doi":"","DOIUrl":"","url":null,"abstract":"Multiple randomized trials and their meta-analysis have demonstrated an overall survival benefit from postmastectomy radiotherapy (PMRT) in women with node-positive breast cancer. However, none of the patients treated in these trials received neoadjuvant chemotherapy, which is now an increasingly common approach. It is unclear how best to apply data from trials conducted in patients treated with adjuvant chemotherapy to this population. To illuminate these issues, this article first reviews the history of PMRT and the current indications for its use based on contemporary data. It focuses on the ways in which staging and outcomes differ for patients who undergo neoadjuvant chemotherapy before mastectomy (as compared with those who receive postoperative adjuvant therapy) and how pathologic features such as response to therapy are correlated with recurrence and survival outcomes. It highlights key information obtained from analysis of the pooled data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) prospective neoadjuvant chemotherapy trials B-18 and B-27 and separate retrospective single-institution studies; this includes the low risk of locoregional recurrence in early-stage patients in whom a pathologic complete response (pCR) was achieved after neoadjuvant chemotherapy without PMRT and the high risk of recurrence in patients with stage III disease, even in the setting of a pCR. It also discusses the ongoing NSABP B-51/Radiation Therapy Oncology Group 1304 and Alliance A011202 trials, which will provide information on whether PMRT can be omitted in patients who have a pathologic complete response (pCR) in the lymph nodes, and whether axillary lymph node dissection will improve recurrence rates compared with sentinel lymph node biopsy and radiotherapy in patients who do not achieve a pCR in the lymph nodes. Finally, it identifies directions for future research. ","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"657-66"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34018129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should Men Diagnosed With Prostate Cancer Hit the Gym? 被诊断患有前列腺癌的男性应该去健身房吗?

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Tom S Feng, Adriana C Vidal, Stephen J Freedland

引用次数: 0

The New Face of Head and Neck Cancer: The HPV Epidemic. 头颈癌的新面孔:HPV流行。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Aaron Lewis, Robert Kang, Alexandra Levine, Ellie Maghami

引用次数: 0

Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. 晚期卵巢癌术中腹腔热化疗的疗效观察。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Anton Oseledchyk, Oliver Zivanovic

{"title":"Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer.","authors":"Anton Oseledchyk, Oliver Zivanovic","doi":"","DOIUrl":"","url":null,"abstract":"Ovarian cancer, because it is largely confined to the peritoneal cavity, has a unique tumor biology and metastatic spread pattern. Its metastatic potential comes from detached tumor cells in the peritoneal cavity that re-attach to the mesothelial lining of the peritoneal surface. It is proposed that these micrometastases without neovasculature, as well as floating malignant cells, are drivers of early recurrence, since they can be neither resected nor adequately treated by systemic chemotherapy. This represents the major rationale for local treatment by means of postoperative intraperitoneal (IP) chemotherapy, which is the standard of care in the United States in patients with advanced-stage ovarian cancer who have minimal residual disease following cytoreductive surgery. An alternative loco-regional treatment strategy is the \"HIPEC\" procedure--hyperthermic IP chemoperfusion that is performed during the operation immediately following completion of gross tumor resection, and which provides improved tissue penetration and distribution of the chemotherapeutics. However, prospective data are limited and an outcomes benefit has yet to be shown. Here we discuss the advantages and pitfalls of HIPEC, as well as current data and ongoing prospective trials.","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"695-701"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34018133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered Questions. 晚期卵巢癌温热腹腔化疗的临床试验:未解之谜。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Maryann Kwa, Franco Muggia

引用次数: 0

Diabetics at increased risk of advanced breast cancer. 糖尿病患者患晚期乳腺癌的风险增加。

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Anna Azvolinsky

引用次数: 0

POINT: Is Cystectomy Needed for Small-Cell Bladder Cancer? 观点:小细胞膀胱癌需要膀胱切除术吗?

Oncology (Williston Park, N.Y.) Pub Date : 2015-09-01

Derek Raghavan